Residual cardiovascular risk in treated hypertension and hyperlipidaemia: The PRIME Study

Journal of Human Hypertension

Volumn 24, Issue 1, 2010, Pages 19-26

  Blacher, J ^a,b   Evans, A ^c   Arveiler, D ^d   Amouyel, P ^e   Ferrieres J ^f   Bingham, A ^a   Yarnell, J ^c   Haas, B ^d   Montaye, M ^e   Ruidavets, J B ^f   Ducimetiere P ^a  

^a HÔPITAL PAUL BROUSSE   (France)

^b HÔTEL DIEU   (France)

^c QUEEN'S UNIVERSITY BELFAST   (United Kingdom)

^d UNIVERSITÉ DE STRASBOURG   (France)

^e INSTITUT PASTEUR DE LILLE   (France)

^f INSERM   (France)

Author keywords

Antihypertensive agents; Epidemiology; Population; Risk prediction

Indexed keywords

ANTIHYPERTENSIVE AGENT; ANTILIPEMIC AGENT;

ARTICLE; CARDIOVASCULAR DISEASE; HUMAN; HYPERLIPIDEMIA; HYPERTENSION; MALE; MIDDLE AGED; PROSPECTIVE STUDY; RISK FACTOR; RISK REDUCTION;

ANTIHYPERTENSIVE AGENTS; ANTILIPEMIC AGENTS; CARDIOVASCULAR DISEASES; HUMANS; HYPERLIPIDEMIAS; HYPERTENSION; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; RISK FACTORS; RISK REDUCTION BEHAVIOR;

EID: 77449117237     PISSN: 09509240     EISSN: 14765527     Source Type: Journal    
DOI: 10.1038/jhh.2009.34     Document Type: Article

References (22)

1. Lauer MS. Clinical epidemiology, clinical care, and the public’s health. Mayo Clin Proc 2004; 79: 983-991.
2. MacMahon S, Peto R, Cutler J, Collins R, Sorlie P, Neaton J et al. Blood pressure, stroke, and coronary heart disease. Part 1, prolonged differences in blood pressure: prospective observational studies corrected for the regression dilution bias. Lancet 1990; 335: 765-774.
3. Collins R, Peto R, MacMahon S, Hebert P, Fiebach NH, Eberlein KA et al. Blood pressure, stroke and coronary heart disease. Part 2, short term reductions in blood pressure: overview of randomised drug trials in their epidemiological context. Lancet 1990; 335: 827-838.
4. Andersson OK, Almgren T, Persson B, Samuelsson O, Hedner T, Wilhelmsen L. Survival in treated hypertension: follow up study after two decades. BMJ1998; 317: 167-171.
5. Glynn RJ, L’Italien GJ, Sesso HD, Jackson EA, Buring JE. Development of predictive models for long-term cardiovascular risk associated with systolic and diastolic blood pressure. Hypertension 2002; 39: 105-110.
6. NCEP. Executive summary of the third report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (adult treatment panel III). JAMA 2001; 285: 2486-2497.
7. Blacher J, Evans A, Arveiler D, Amouyel P, Ferrieres J, Bingham A, et al., on behalf of the PRIME Study Group. Residual coronary risk in men aged 50-59 treated for hypertension and hyperlipidemia in the population. The PRIME study. J Hypertens 2004; 22: 415-423.
8. D’Agostino Sr RB, Vasan RS, Pencina MJ, Wolf PA, Cobain M, Massaro JM et al. General cardiovascular risk profile for use in primary care: the Framingham Heart Study. Circulation 2008; 117: 743-753.
9. Hippisley-Cox J, Coupland C, Vinogradova Y, Robson J, May M, Brindle P. Derivation and validation of QRISK, a new cardiovascular disease risk score for the United Kingdom: prospective open cohort study. BMJ 2007; 335: 136-147.
10. Zethelius B, Berglund L, Sundstrom J, Ingelsson E, Basu S, Larsson A et al. Use of multiple biomarkers to improve the prediction of death from cardiovascular causes. N Engl J Med 2008; 358: 2107-2116.
11. Yarnell JWG, for the PRIME Study Group. The PRIME study: classical risk factors do not explain the severalfold differences in risk of coronary heart disease between France and Northern Ireland. Q J Med 1998; 91: 667-676.
12. Ducimetiere P, Ruidavets JB, Montaye M, Haas B, Yarnell J, on behalf of the PRIME Study Group. Five-year incidence of angina pectoris and other forms of coronary heart disease in healthy men aged 50-59 in France and Northern Ireland: the PRIME study. Int J Epidemiol 2001; 30: 1057-1062.
13. Rose GA, Blackburn H, Gillum RF, Prineas RJ. Cardiovascular Survey Methods, 2nd edn. WHO: Geneva, 1982.
14. Tunstall-Pedoe H, Kuulasmaa K, Amouyel P, Arveiler D, Rajakangas A-M, Pajak A, for WHO MONICA Project. Myocardial infarction and coronary deaths in the World Health Organization MONICA Project. Registration procedures, event rates and case fatality in 38 populations from 21 countries in 4 continents. Circulation 1994; 90: 583-612.
15. Mancia G, De Backer G, Dominiczak A, Cifkova R, Fagard R, Germano G et al. Management of arterial hypertension of the European Society of Hypertension; European Society of Cardiology. 2007 guidelines for the management of arterial hypertension: the task force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens 2007; 25: 1105-1187.
16. Lindholm LH, Carlberg B, Samuelsson O. Should beta-blockers remain first choice in the treatment of primary hypertension? A meta-analysis. Lancet 2005; 366: 1545-1553.
17. Verdecchia P, Reboldi G, Angeli F, Gattobigio R, Bentivoglio M, Thijs L et al. Angiotensin-converting enzyme inhibitors and calcium channel blockers for coronary heart disease and stroke prevention. Hypertension 2005; 46: 386-392.
18. Siscovick DS, Raghunathan TE, Psaty BM, Koepsell TD, Wicklund KG, Lin X et al. Diuretic therapy for hypertension and the risk of primary cardiac arrest. NEngl J Med 1994; 330: 1852-1857.
19. Turnbull F. Blood pressure lowering treatment trialists’ collaboration. Effects of different blood-pressure-lowering regimens on major cardiovascular events: results of prospectively-designed overviews of randomised trials. Lancet 2003; 362: 1527-1535.
20. The ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker versus diuretic: the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA 2002; 288: 2981-2997.
21. Takemoto M, Liao JK. Pleiotropic effects of 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibitors. Arterioscler Thromb Vasc Biol 2001; 21: 1712-1719.
22. Cholesterol Treatment Trialists’ (CTT) Collaborators. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90 056 participants in 14 randomised trials of statins. Lancet 2005; 366: 1267-1278.